Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 24 04:00PM ET
4.21
Dollar change
+0.13
Percentage change
3.19
%
IndexRUT P/E- EPS (ttm)-0.50 Insider Own3.06% Shs Outstand82.07M Perf Week11.67%
Market Cap356.33M Forward P/E- EPS next Y-0.64 Insider Trans-2.47% Shs Float82.05M Perf Month-6.44%
Income-40.59M PEG- EPS next Q-0.14 Inst Own37.77% Short Float26.59% Perf Quarter-9.66%
Sales0.00M P/S- EPS this Y13.33% Inst Trans-1.98% Short Ratio18.03 Perf Half Y-52.43%
Book/sh1.62 P/B2.60 EPS next Y-23.08% ROA-26.71% Short Interest21.82M Perf Year-49.28%
Cash/sh1.65 P/C2.56 EPS next 5Y- ROE-28.96% 52W Range3.25 - 10.45 Perf YTD-54.78%
Dividend Est.- P/FCF- EPS past 5Y-9.03% ROI-30.03% 52W High-59.71% Beta0.63
Dividend TTM- Quick Ratio15.12 Sales past 5Y0.00% Gross Margin- 52W Low29.54% ATR (14)0.23
Dividend Ex-Date- Current Ratio15.12 EPS Y/Y TTM26.81% Oper. Margin0.00% RSI (14)58.12 Volatility6.15% 5.64%
Employees40 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price27.50
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q23.60% Payout- Rel Volume0.70 Prev Close4.08
Sales Surprise- EPS Surprise-18.18% Sales Q/Q- EarningsMay 09 BMO Avg Volume1.21M Price4.21
SMA206.68% SMA506.27% SMA200-26.29% Trades Volume845,732 Change3.19%
Date Action Analyst Rating Change Price Target Change
Dec-06-22Downgrade Cantor Fitzgerald Overweight → Neutral $16 → $11
Jun-23-22Initiated Berenberg Buy $40
Sep-23-21Initiated BTIG Research Buy $35
Dec-16-20Reiterated H.C. Wainwright Buy $14 → $17
Sep-28-20Initiated Ladenburg Thalmann Buy $12
Feb-27-20Initiated Cantor Fitzgerald Overweight
Jun-18-19Initiated Janney Buy
May-16-18Resumed Maxim Group Buy $5 → $7
Mar-08-18Initiated ROTH Capital Buy $6
Feb-13-18Reiterated Maxim Group Buy $14 → $5
Jun-20-24 07:30AM
May-22-24 07:30AM
May-15-24 12:00PM
May-14-24 10:15AM
07:30AM
11:18AM Loading…
May-10-24 11:18AM
May-09-24 07:41AM
07:30AM
May-02-24 07:30AM
Apr-22-24 05:45AM
Apr-11-24 07:30AM
Mar-31-24 01:46AM
Mar-28-24 01:18PM
Mar-25-24 11:55AM
07:30AM
07:30AM Loading…
Mar-18-24 07:30AM
Mar-15-24 05:45AM
Mar-04-24 11:46AM
Feb-26-24 01:14PM
07:30AM
Feb-08-24 09:39AM
Feb-07-24 07:43AM
07:30AM
Feb-01-24 07:30AM
Jan-31-24 09:55AM
Jan-24-24 12:00PM
07:30AM
Jan-16-24 07:30AM
Jan-12-24 10:10AM
Jan-09-24 08:44AM
07:30AM Loading…
Jan-08-24 07:30AM
Jan-03-24 12:14PM
09:51AM
07:30AM
Jan-02-24 08:00AM
Dec-20-23 11:09AM
10:45AM
07:30AM
Dec-19-23 07:30AM
Dec-18-23 09:55AM
Dec-01-23 08:09AM
Nov-30-23 09:55AM
Nov-27-23 08:10AM
08:00AM
Nov-24-23 08:00AM
Nov-22-23 08:00AM
Nov-21-23 08:19AM
Nov-20-23 08:00AM
Nov-06-23 08:00AM
Oct-30-23 03:46PM
Oct-25-23 08:00AM
Sep-14-23 07:30AM
Sep-12-23 07:30AM
Aug-08-23 09:43PM
07:58AM
07:30AM
Aug-07-23 07:30AM
Aug-02-23 07:30AM
Aug-01-23 07:30AM
Jul-03-23 07:43AM
Jun-28-23 07:30AM
Jun-27-23 07:30AM
Jun-20-23 07:30AM
Jun-15-23 07:30AM
Jun-12-23 07:30AM
Jun-08-23 09:40AM
Jun-06-23 07:30AM
Jun-01-23 07:30AM
May-31-23 09:55AM
May-15-23 09:55AM
May-10-23 02:47PM
May-09-23 09:51PM
07:46AM
07:30AM
May-02-23 07:30AM
May-01-23 07:30AM
Apr-25-23 07:30AM
Apr-10-23 07:00AM
Apr-06-23 10:19AM
Apr-03-23 02:20PM
Mar-30-23 07:00AM
Mar-15-23 09:53AM
Mar-13-23 10:19AM
Mar-09-23 07:00AM
Mar-06-23 08:21PM
Feb-23-23 10:00AM
Feb-15-23 09:55AM
Feb-09-23 08:45AM
Feb-08-23 02:36PM
10:16AM
Feb-07-23 02:33PM
07:00AM
Feb-02-23 07:00AM
Jan-31-23 07:00AM
Jan-23-23 09:11AM
Jan-20-23 12:52PM
Jan-18-23 08:00AM
Dec-17-22 09:15AM
Dec-15-22 11:19AM
Dec-14-22 07:00AM
Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Donhauser Peter D.O.DirectorJun 14 '24Buy3.642,83510,3195,000Jun 17 07:30 AM
Thomas SteffenDirectorMay 15 '24Buy4.525,00022,6005,000May 17 06:01 AM
MISSLING CHRISTOPHER UPresident and CEOMar 28 '24Option Exercise1.3273,38096,8621,323,590Apr 01 06:00 PM
MISSLING CHRISTOPHER UPresident and CEOMar 28 '24Sale5.1173,380374,9721,250,210Apr 01 06:00 PM
MISSLING CHRISTOPHER UPresident and CEOJun 29 '23Option Exercise1.60232,000371,2001,250,210Jun 30 08:00 PM
MISSLING CHRISTOPHER UPresident and CEOJun 28 '23Option Exercise1.60268,000428,8001,286,210Jun 30 08:00 PM
MISSLING CHRISTOPHER UPresident and CEOJun 28 '23Sale7.98268,0002,139,3101,018,210Jun 30 08:00 PM